drugset / Trial / NCT03631771
Pediatric Risk of Hypothyroidism With Iodinated Contrast Media
NaSingle-groupOpen-labelOther
Summary
This is a Phase 4 multicenter prospective study to estimate the proportion of patients aged birth to 3 years who develop hypothyroidism within 6 months after receiving intravascular iohexol (Omnipaque™), iodixanol (Visipaque™), iopromide (Ultravist®), or ioversol (Optiray®) as the iodinated contrast medium (ICM) for clinical evaluation during an ICM-enhanced diagnostic imaging procedure.
Timeline
- Start
- 2022-03
- Primary completion
- 2024-08
- Completion
- 2025-02
Outcome
Outcome not reported
Stopped: “It was determined that a study is no longer required because the clinical question posed by the study has been answered through published literature”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Iodixanol | Diagnostic / imaging agent | — | Other |
| Subject | Iohexol | Diagnostic / imaging agent | — | Other |
| Subject | Iopromide | Diagnostic / imaging agent | — | Other |
| Subject | Ioversol | Small molecule | — | Other |